SEATTLE, WA--(Marketwire - Mar 6, 2013) - Integrated Diagnostics (Indi®), an emerging leader in molecular diagnostics, today announced that it has appointed John Bencich as chief financial officer and Jill Tonachio as vice president for sales. The two executives will play key roles in the launch of the company's first commercial product later this year, a blood test for the early diagnosis of lung cancer. Bencich, who most recently served as the CFO of Allozyne, brings extensive experience as a financial executive for life sciences companies. Tonachio, a sales executive with deep expertise in diagnostics, was most recently national director of sales for Aurora Diagnostics.
"As Indi prepares for the commercial launch of our first product -- a blood test for the diagnosis of lung cancer -- I am enormously pleased to have John Bencich and Jill Tonachio on our team," said Albert "Al" A. Luderer, Ph.D., CEO of Indi. "John has a wealth of experience at successfully navigating the financial and operational issues that young life sciences companies face. Jill brings a superb track record of success in diagnostics sales and customer support. With our full commercial team now in place, I am confident that we will have a successful launch of Indi's lung cancer diagnostic."
Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to diagnose diseases at their earliest stages. By monitoring blood proteins that are only synthesized in the organ of interest, the company's diagnostics gather systems level knowledge to identify subtle changes that result from disease or treatment. The company is also creating a new generation of PET imaging probes using the company's innovative protein catalyzed capture (PCC) agent technology.
About John Bencich
As Indi's CFO, Bencich leads the company's finances and strategic company-building objectives. Prior to joining Indi, he was Allozyne's chief financial officer. Earlier Bencich served as the vice president, chief financial officer and treasurer of Trubion Pharmaceuticals, a biotechnology company, until its acquisition by Emergent BioSolutions. Before that he was the director of finance and corporate controller for Onyx Software Corporation. Bencich started his career at Ernst & Young, the international professional services firm.
Bencich received a B.A. in accountancy from the University of San Diego and an M.B.A. from Seattle University. He received his CPA certification from Washington State and currently holds an active license.
About Jill Tonachio
As Indi's VP for sales, Tonachio leads the company's sales team, responsible for driving the introduction and adoption of the company's diagnostics. Prior to joining Indi, Tonachio held several positions at Aurora Diagnostics, most recently serving as their national director of sales. Before that she served as director of strategic accounts at Aureon Laboratories. Earlier in her career she worked for Laboratory Corporation of America and DIANON Systems, holding several positions, including regional manager for business development. She began her career in life sciences as a senior sales representative for Johnson & Johnson.
Tonachio holds a bachelor of science degree in business logistics from Pennsylvania State University.
About Integrated Diagnostics
Integrated Diagnostics' mission is to build new generations of cost-effective, large-scale molecular diagnostic products for improved diagnosis of complex diseases with high unmet needs. Indi Dx™, the company's in vitro diagnostic medicine division, is developing complex laboratory-developed molecular diagnostic tests that assist physicians with the early diagnosis of diseases like lung cancer and Alzheimer's by simultaneously monitoring tens to hundreds of disease molecular markers. Integrated Diagnostics' other division, Indi Imaging, is creating new generations of in vivo molecular imaging diagnostic products based on a novel class of small-molecule diagnostic imaging probes that mimic the properties of biologics and antibodies using InDi's protein-catalyzed capture (PCCs) agent technology.
The company, co-founded in October 2009 by systems biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.integrated-diagnostics.com